Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
CA: A Cancer Journal for Clinicians · 2023-03 · 73 (2) · 198-222
DOI: 10.3322/caac.21759 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 19.10.2022. Verfasst von Dimitrios Moris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Antineoplastic Agents, Bile Duct Neoplasms. Die Arbeit wurde bisher 385-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially curative treatment; and, after resection, a median survival of 53 months has been reported when sequenced with adjuvant capecitabine. For the 70%–80% of patients who present with locally unresectable or distant metastatic disease, systemic therapy may delay progression, but survival remains limited to approximately 1 year. For the past decade, doublet chemotherapy with gemcitabine and cisplatin has been considered the most effective first‐line regimen, but results from the recent use of triplet regimens and even immunotherapy may shift the paradigm. More effective treatment strategies, including those that combine systemic therapy with locoregional therapies like radioembolization or hepatic artery infusion, have also been developed. Molecular therapies, including those that target fibroblast growth factor receptor and isocitrate dehydrogenase, have recently received US Food and Drug Administration approval for a defined role as second‐line treatment for up to 40% of patients harboring these actionable genomic alterations, and whether they should be considered in the first‐line setting is under investigation. Furthermore, as the oncology field seeks to expand indications for immunotherapy, recent data demonstrated that combining durvalumab with standard cytotoxic therapy improved survival in patients with ICC. This review focuses on the current and future strategies for ICC treatment, including a summary of the primary literature for each treatment modality and an algorithm that can be used to drive a personalized and multidisciplinary approach for patients with this challenging malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Dimitrios Moris
Zitieren
APA
Moris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2023). Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA: A Cancer Journal for Clinicians, 73(2), 198-222. https://doi.org/10.3322/caac.21759
Vancouver
Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA: A Cancer Journal for Clinicians. 2023;73(2):198-222. doi:10.3322/caac.21759
BibTeX
@article{Moris2023,
author = {Moris, Dimitrios and Palta, Manisha and Kim, Charles and Allen, Peter J and Morse, Michael A and Lidsky, Michael E},
title = {Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians},
journal = {CA: A Cancer Journal for Clinicians},
year = {2023},
volume = {73},
number = {2},
pages = {198--222},
doi = {10.3322/caac.21759}
}
EUVIMED